<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02478047</url>
  </required_header>
  <id_info>
    <org_study_id>2014CB543202-01</org_study_id>
    <nct_id>NCT02478047</nct_id>
  </id_info>
  <brief_title>Comparative Effect Study Between Distal-proximal Point Association and Local Distribution Point Association in Chemotherapy-induced Nausea and Vomiting</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Basic Research Program, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to clarify whether distal-proximal point association is more
      effective than partial match point association by electro-acupuncture in the management of
      chemotherapy-induced nausea and vomiting .
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the frequency of Nausea and Vomiting</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the extent of Nausea and Vomiting</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rhodes Index of Nausea, Vomiting and Retching</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the condition of constipation and diarrhea</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gastric electrical activity (electrogastrogram)</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the life quality of the patients</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Anxiety and Depression of the patients</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>the number of blood cells</measure>
    <time_frame>3 weeks</time_frame>
    <description>the number of WBC,RBC,hemoglobin,PLT,the percents of GRA,LYM</description>
  </other_outcome>
  <other_outcome>
    <measure>cardial electrical activity</measure>
    <time_frame>3 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>hepatic function</measure>
    <time_frame>3 weeks</time_frame>
    <description>The Outcome Measures will be assessed by blood, the metrics of ALT,AST,TBIL is IU/L,IU/L,and μmol/L.</description>
  </other_outcome>
  <other_outcome>
    <measure>other adverse effect during the chemotherapy</measure>
    <time_frame>3 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>renal function</measure>
    <time_frame>3 weeks</time_frame>
    <description>The Outcome Measures will be assessed by blood, the metrics of BUN,Scr is mmol/L and μmol/L.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Chemotherapy-induced Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>only antiemetic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participants in the control group received standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology cClinical pPractice gGuideline. The 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are administered before the chemotherapy treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching points ST36+CV12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching points PC6+CV12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching points CV3+CV12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>only antiemetic (Ramosetron, Tropisetron and dexamethasone)</intervention_name>
    <description>The control group will receive standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are supplied from the first day of chemotherapy, and lasting for 3-5 days.And plus antiemetic drug as the comparator group.</description>
    <arm_group_label>only antiemetic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Matching points ST36+CV12 plus antiemetic drug</intervention_name>
    <description>Choose both Zusanli(ST36) and Zhongwan point(CV12). Manipulating until achieving a &quot;de Qi&quot; sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group.</description>
    <arm_group_label>Matching points ST36+CV12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Matching points PC6+CV12 plus antiemetic drug</intervention_name>
    <description>Choose both Neiguan(PC6) and Zhongwan point(CV12). Manipulating until achieving a &quot;de Qi&quot; sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group.</description>
    <arm_group_label>Matching points PC6+CV12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Matching points CV13+CV12 plus antiemetic drug</intervention_name>
    <description>Choose both Shangwan(CV13) and Zhongwan point(CV12). Manipulating until achieving a &quot;de Qi&quot; sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group.</description>
    <arm_group_label>Matching points CV3+CV12</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be diagnosed as cancer and need to accept chemotherapy.

          2. The score of Karnofsky ≥70

          3. Patients of either gender and older than 18 years

          4. Patients receiving chemotherapy both outpatients and inpatients

          5. Patients receiving chemotherapy either the first or multiple cycle, but the patient
             will be taken in only one time

          6. To receive chemotherapy containing cisplatin(DDP≥75mg/m2) or joint chemotherapy
             programmes of Anthracyclines(Adriamycin≥40mg/m2 or epirubicin≥60mg/m2)

          7. Life expectancy≥ 6 months

          8. Willing to participate in the study and be randomized into one of the four study
             groups.

        Exclusion Criteria:

          1. To receive radiotherapy and chemotherapy

          2. Gastrointestinal tumors

          3. Patients with serious liver disease or abnormal hepatorenal function (AST,ACT, and
             TBIL are 3 times more than normal, BUN and Cr are 2 times more than normal)

          4. Presence of cardiac pacemaker

          5. Active skin infection

          6. Nausea and/or vomiting resulting from opioids or metabolic imbalance (electrolyte
             disturbances)

          7. Patients unable to provide self-care or communication

          8. Nausea and/or vomiting resulting from mechanical risk factors (i.e., intestinal
             obstruction)

          9. Brain metastases

         10. Women in pregnant and lactating period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tianjin University of TCM</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300193</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guo Yi, Doc</last_name>
      <phone>13920921016</phone>
      <email>tjutcmacupuncture@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2015</study_first_submitted>
  <study_first_submitted_qc>June 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2015</study_first_posted>
  <last_update_submitted>June 22, 2015</last_update_submitted>
  <last_update_submitted_qc>June 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tianjin University of Traditional Chinese Medicine</investigator_affiliation>
    <investigator_full_name>Yi Guo</investigator_full_name>
    <investigator_title>the Dean of Acupuncture and Moxibustion College</investigator_title>
  </responsible_party>
  <keyword>to Evaluate the Effectiveness of Acupucnture in the Management of Chemotherapy-induced Nausea and Vomiting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Antiemetics</mesh_term>
    <mesh_term>Ramosetron</mesh_term>
    <mesh_term>Tropisetron</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

